拉米耐药可能应直接用恩替1.0mg治疗(4月19日于EASL)

zasxz

HBV Patients Unresponsive to Lamivudine (Epivir-HBV) May Be Switched Directly to Therapy with Entecavir 1.0 Mg Daily Hepatic flares have been reported in patients who have been abruptly discontinued from anti-HBV therapy.?In a phase II, multinational, double-blind, randomized, 4-arm, dose-ranging trial, ALT elevations and hepatic adverse events were analyzed in 181 lamivudine (LVD)-refractory patients (87% with YMDD mutations) switched directly to entecavir (ETV) at one of three doses (0.1, 0.5, 1.0 mg daily) or continued on LVD therapy (100mg daily).? Post-switch ALT flares were defined as ALT>2x baseline (BL) and >10x upper limit of normal (ULN). Patients were treated for up to 85 weeks. Results Eleven patients (6%) developed ALT flares during study treatment: 3 on 1.0mg, 1 on 0.5mg, 2 on 0.1mg ETV and 5 on continued LVD.? All 4 patients on either 0.5 or 1.0 mg ETV had transient ALT flares that?resolved while on continued blinded ETV therapy; all had declines in HBV bDNA 揙n-treatment ALT elevations accompanied by viral load reductions may reflect a favorable response to therapy.?/span> 04/19/04 Reference R G Gish and others. LAMIVUDINE-REFRACTORY HEPATITIS B PATIENTS CAN BE SAFELY SWITCHED DIRECTLY TO ENTECAVIR 1 MG DAILY THERAPY. Abstract 428.?39th EASL. April 14-18, 2004. Berlin, Germany.

及时雨

谁给翻译一下。感谢。

及时雨

没人翻译？